预约演示

更新于：2025-09-08

Tenofovir

替诺福韦

更新于：2025-09-08

概要

基本信息

药物类型

小分子化药

别名

(R)-PMPA、Anhydrous tenofovir、Tenofovir (anh.)

+ [16]

靶点

作用方式

抑制剂

作用机制

RT抑制剂(逆转录酶抑制剂)

治疗领域

感染免疫系统疾病消化系统疾病+ [1]

在研适应症

病毒感染慢性乙型肝炎HIV感染

非在研适应症

性交困难乙型肝炎病毒相关肝细胞癌单纯疱疹+ [3]

原研机构

Gilead Sciences, Inc.

在研机构

Gilead Sciences, Inc.

Lauren Sciences LLC

Pharmacare Srl

非在研机构

ViiV Healthcare Ltd.

Contraception Research and Development

GSK Plc

权益机构

International Partnership for Microbicides

Gilead Sciences, Inc.

Contraception Research and Development

最高研发阶段批准上市

首次获批日期

中国 (2008-06-18),

病毒感染

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C9H16N5O5P

InChIKeyPINIEAOMWQJGBW-FYZOBXCZSA-N

CAS号206184-49-8

关联

283

项与替诺福韦相关的临床试验

NCT07133763

/ Not yet recruiting临床1/2期IIT

A Multicenter, Single-Arm, Prospective Study to Evaluate the Efficacy and Safety of PD-1 Inhibitor Combined With Tenofovir, Chidamide, and Lenalidomide in the Treatment of Relapsed or Refractory EBV-Associated Lymphoproliferative Disorders.

This study is a prospective, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of PD-1 inhibitor combined with tenofovir, chidamide, and lenalidomide in the treatment of relapsed or refractory Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPDs). The primary endpoint is the overall response rate (ORR) at 3 months, including complete response (CR) and partial response (PR). Secondary endpoints include overall survival (OS), progression-free survival (PFS), as well as safety and tolerability assessments. Eligible patients must have histologically confirmed EBV-positive B-cell or T/NK-cell LPDs with measurable lesions. This combination regimen targets multiple mechanisms, including inhibition of EBV replication, activation of the immune system, and enhancement of antitumor effects, aiming to provide an innovative therapeutic strategy for this challenging disease.

开始日期2025-09-01

申办/合作机构

徐州医科大学附属医院

NCT07133776

/ Not yet recruiting临床1/2期IIT

A Multicenter, Single-Arm, Prospective Clinical Study to Evaluate the Efficacy and Safety of PD-1 Inhibitor Combined With Tenofovir, Chidamide, and Lenalidomide in the Treatment of EBV-Associated Diseases

Currently, treatment options for Epstein-Barr virus (EBV) infection are limited, with unsatisfactory efficacy and no established standard therapy. Therefore, our center is conducting a prospective, multicenter, single-arm clinical trial to evaluate the efficacy and safety of PD-1 inhibitor in combination with tenofovir, chidamide, and lenalidomide in patients with EBV infectious diseases, aiming to provide a more effective and safer therapeutic option for EBV infectious diseases.

开始日期2025-09-01

申办/合作机构

徐州医科大学附属医院

NCT07095855

/ Not yet recruiting临床3期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R (Canocapavir) in Combination With Nucleos(t)Ide Analog(NAs) Compared With NAs Monotherapy in Patients With Chronic Hepatitis B Who Have Received NAs Monotherapy for at Least 12 Months

This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs monotherapy with HBV DNA ≥ 50 IU/mL and are HBeAg positive who have received NAs monotherapy for at least 12months.Part B is an open-label extension and follow-up period designed to evaluate the long-term safety and efficacy of ZM-H1505R in combination with NAs.

开始日期2025-08-01

申办/合作机构

上海挚盟医药科技有限公司

100 项与替诺福韦相关的临床结果

登录后查看更多信息

100 项与替诺福韦相关的转化医学

登录后查看更多信息

100 项与替诺福韦相关的专利（医药）

登录后查看更多信息

6,407

项与替诺福韦相关的文献（医药）

2025-12-31·HIV Research & Clinical Practice

Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm

Article

BACKGROUND:

Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of Emtricitabine/Tenofovir (TDF/FTC) in active-controlled pre-exposure prophylaxis (PrEP) trials has been suggested. However, it has not yet been widely applied. In this article, we evaluate adherence to TDF/FTC in the PrEPVacc trial (NCT04066881) and consider how such adherence data could be used to estimate the effectiveness of TDF/FTC and subsequently, HIV incidence in a counterfactual placebo arm in a predominantly female population.

METHODS:

From December 2020 to March 2023 participants were recruited into the trial which included a comparison of Emtricitabine/Tenofovir Alafenamide (TAF/FTC) to TDF/FTC as PrEP over 26 weeks of follow-up, in Uganda, Tanzania, and South Africa. PrEP adherence was assessed in various ways.

RESULTS:

Of 697 participants dispensed TDF/FTC, 87% were female, 54% were ≥ 25 years, and 59% were sex workers. In a random sample (41%) assessed at visit 6 (week 8), 76% had detectable TFV-DP levels, with 22% reaching levels consistent with ≥2 pills/week. Males, Verulam and Mbeya participants, those ≥ 25 years, not single, subsistence fisheries workers, and those who had any STI at baseline were more likely to have higher adherence. Of those assessed at visit 6, 29% were identified as white coat dosing. Estimated (crude) HIV incidence risk reduction ranged from 10% to 65%.

CONCLUSIONS:

TDF/FTC adherence in the PrEPVacc trial was low, with considerable levels of white coat dosing. Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of TDF/FTC is a promising approach, however, the approach requires further elaboration and evaluation.

2025-12-31·Global Health Action

Low-level viremia in people with HIV in Ethiopia is associated with subsequent lack of viral suppression and attrition from care

Article

作者: Abdissa, Alemseged ; Björkman, Per ; Abdulahi, Ilili Jemal ; Reepalu, Anton ; Elvstam, Olof ; Medstrand, Patrik

BACKGROUND:

Low-level viremia during antiretroviral therapy (ART) has been associated with inferior outcomes, but knowledge on the impact of low-level viremia in the current era of dolutegravir-based ART in low-income countries is limited.

OBJECTIVE:

To investigate whether low-level viremia predicts virologic non-suppression and attrition from care in people with HIV receiving ART in Ethiopia.

METHODS:

We included people receiving ART at public health facilities in an urban area in central Ethiopia and categorized persons with ≥1 available viral load 2019-2020 as having either suppression (<150 copies/mL) or low-level viremia (151-1,000 copies/mL); people with >1,000 copies/mL were excluded. We used multivariable logistic regression adjusted for age, sex, ART regimen, type of health facility, and duration of ART to analyze the associations between viremia category and incidence of unsuppressed viral load (>1,000 copies/mL) and attrition from care (death or loss to follow-up) during 3 years of follow-up.

RESULTS:

Among 12,165 participants, the median age was 44 years, 64.2% were female, and 89.1% received tenofovir/lamivudine/dolutegravir. Of the study population, 11,959 (98.3%) had suppression and 206 (1.7%) had low-level viremia. Over 3 years of follow-up, 2.2% of participants with suppression and 11.3% with low-level viremia had unsuppressed viral load. Low-level viremia was associated with both unsuppressed viremia (adjusted odds ratio [aOR], 3.7; 95% confidence interval [CI], 2.2-6.2) and attrition (aOR, 3.4; 95% CI, 1.7-6.6).

CONCLUSION:

Among Ethiopian people with HIV receiving ART, low-level viremia predicted subsequent virologic non-suppression and attrition from care, supporting current recommendations for heightened attention to low-level viremia in ART recipients.

2025-10-01·Advances in Medical Sciences

Prevalence of hepatitis D virus in chronic hepatitis B patients: findings from Poland

Article

作者: Piszcz, Agnes ; Pleśniak, Robert ; Brzdęk, Kinga ; Martonik, Diana ; Parfieniuk-Kowerda, Anna ; Zarębska-Michaluk, Dorota ; Flisiak, Robert ; Dobrowolska, Krystyna ; Brzdęk, Michał ; Janczura, Jakub

PURPOSE:

This study aimed to determine the prevalence of hepatitis B/hepatitis D virus (HBV/HDV) co-infections in eastern Poland.

MATERIALS/METHODS:

We included consecutive patients with chronic hepatitis B treated with nucleos(t)ide analogues (NA) in the study, in whom we performed anti-HDV assays verified by molecular testing.

RESULTS:

The analysed population consisted of 398 patients, predominantly male with a median age of 50 years, 58.3 % of whom had comorbidities. Forty-three patients (10.8 %) were diagnosed with cirrhosis. Patients were treated with entecavir, tenofovir, or lamivudine for a median of 5 years. At the start of treatment, the median viral load was 5110 IU/ml, and 98 % of patients achieved viral eradication during the therapy. In the study population, anti-HDV antibodies were detected in 6 patients (1.5 %), 3 men and 3 women, of whom in 1 (0.25 %) the presence of genetic material of the HDV was confirmed by molecular testing. Among anti-HDV-positive patients, 3 (50 %) had cirrhosis, 1 of them underwent liver transplantation, and 2 had extrahepatic malignancy. All of them were negative for hepatitis B virus envelope (HBe) antigen and had antibodies to HBe antigen present at the beginning of antiviral treatment. All anti-HDV-positive patients achieved viral clearance during the therapy.

CONCLUSION:

In a population of almost four hundred patients infected with HBV, we observed a low prevalence of anti-HDV antibodies of 1.5 % and HDV replication of only 0.25 %. Half of the 6 patients with serologic evidence of co-infection had cirrhosis, so HDV likely played a role in disease progression.

300

项与替诺福韦相关的新闻（医药）

2025-08-26

·Firstwordpharma

EU okays Gilead’s twice-yearly HIV PrEP shot Yeytuo

The European Commission approved Gilead Sciences' Yeytuo (lenacapavir) under an accelerated timeline, making it the first twice-yearly injectable pre-exposure prophylaxis (PrEP) option authorised in the region.After its earlier EU clearance in 2022 under the name Sunlenca to treat multi-drug-resistant HIV, the capsid inhibitor this time is indicated for reducing the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg with increased HIV-1 acquisition risk.The “rapid authorisation…underscores the…transformative potential of Yeytuo to help address the urgent unmet need in HIV prevention across Europe," said Dietmar Berger, chief medical officer at Gilead.The accelerated European clearance, which comes after the therapy’s US approval in June as Yeztugo, is supported by data from two Phase III trials. PURPOSE 1 demonstrated zero HIV infections with twice-yearly Yeytuo — a 100% reduction compared with once-daily oral Truvada (emtricitabine/tenofovir) in cisgender women in sub-Saharan Africa. Meanwhile, PURPOSE 2 showed 99.9% of cisgender men and gender-diverse participants receiving Yeytuo remained HIV-free with superior prevention efficacy versus Truvada.Gilead, at the beginning of the year, was said to be heavily banking on the PrEP’s commercial success amid pricing reforms and a slow oncology pipeline. A recent FirstWord physician poll showed nearly 90% of respondents expect the product’s twice-yearly dosing to moderately or significantly improve patient adherence and satisfaction.The drugmaker also noted Yeytuo will gain an extra year of European market protection after the regulator deemed the new indication offers significant clinical benefit over existing therapies. The therapy also remains under regulatory review in Australia, Brazil, Canada, South Africa and Switzerland, with filings prepped in several other countries.Meanwhile, the company is set to commence late-stage testing of a once-yearly lenacapavir formulation this year.

临床3期上市批准临床结果

2025-08-18

·PMLiVE

Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the US Food and Drug Administration (FDA) for expanded human immunodeficiency virus (HIV) use. The drug is now authorised to treat HIV in patients with an antiretroviral treatment history who are not virologically suppressed, with no known or suspected resistance to the integrase strand inhibitor class, emtricitabine or tenofovir. An estimated 1.2 million people in the US are currently living with HIV, a virus that weakens the immune system and increases the risk of serious illness. Taken orally once daily, Biktarvy is a complete HIV treatment that combines three medicines in a single pill and reduces the amount of HIV in the blood to undetectable levels. It is already approved for a range of HIV-1 patient populations. The new indication will help address a “critical unmet need”, Gilead said, as currently only 65% of HIV patients are estimated to be virally suppressed at any point in time, and many interrupt and later need to restart treatment. The FDA’s latest decision was supported by the “strength of evidence” for Biktarvy from two treatment naïve studies, the company outlined. The drug was associated with rapid and durable viral suppression, and demonstrated an established long-term safety and tolerability profile, and zero cases of treatment-emergent resistance to Biktarvy over five years. Jared Baeten, senior vice president, virology therapeutic area head, Gilead, said: “Continuous scientific discoveries and person-centric advances in HIV care have helped transform the treatment landscape. At the same time, not everyone is achieving long-term HIV treatment success, especially when someone experiences an interruption in their HIV care. “With this new indication, Biktarvy can now support an even broader range of people with HIV in reaching their long-term treatment goals, including those who are not virologically suppressed and who are restarting treatment.” HIV is a key focus area for Gilead, with the authorisation coming less than two months after the company’s twice-yearly injectable pre-exposure prophylaxis (PrEP) drug received FDA approval to prevent HIV. Yeztugo (lenacapavir), which was authorised to reduce the risk of sexually-acquired HIV in adults and adolescents weighing at least 35kg, is now the first PrEP option in the US that offers six months of protection against the virus.

上市批准临床研究免疫疗法

2025-08-11

·医药投资部落

从吉利德研发核心大咖到柯君医药创始人：何公钦博士与AI+前药技术的全球突破

奥司他韦精准抑制流感病毒，索磷布韦实现丙肝临床治愈，依福格雷（CG-0255）在抗血小板治疗中显示出独特潜力——这些医学突破背后，一种名为“前药”的技术正逐渐走入公众视野。通过化学修饰让药物“伪装”穿越生物屏障、在靶区精准释放，这项技术已从最初优化药代动力学的辅助工具，演变为药物研发的核心策略之一。在前药技术的迭代进程中，何公欣博士的轨迹颇具代表性。这位曾参与吉利德多款重要前药研发的科学家，2018年在上海创立柯君医药，尝试以“AI+空间化学”探索新一代前药技术。这一个人职业转向的背后，折射出中国创新药企在全球前药研发领域的突围尝试。何公钦博士带领研发团队主导或直接参与研发的已上市产品——基于前药技术平台及抗病毒药物技术平台开发的重磅Best-in-Class新药从吉利德到柯君医药何公欣博士的职业经历与前药技术产业化的关键阶段高度重合。他的学术根基扎根于华东理工大学合成化学专业，后赴日本九州大学深耕有机合成与药物化学，又在美国加州大学完成博士后研究，系统构建了药物设计与化学合成的双重能力。这为他日后投身前药领域研发，奠定了坚实的基础。博士后研究结束后，何公欣博士加入了处于高速成长期的吉利德。在吉利德近30年的研发生涯中，他深度参与并推动了前药技术的发展，不仅主导多个国际“同类最佳”新药研发，更作为主要发明人及研发项目负责人，推动了目前全球广泛使用的抗乙肝病毒药物替诺福韦新一代前药——替诺福韦艾拉酚胺（TAF）的诞生。此外，他还是多个抗病毒疗法的共同发明人，在心脑血管、核酸药物及多种抗病毒治疗领域积累了深厚经验。何博士参与编写的前药技术相关专著 2008年，何公欣博士回国出任吉利德中国区首席代表及首任总经理，负责吉利德在国内搭建区域分部工作。在此期间，何公欣博士从一位药物研发者逐渐成为一位负责生产运营、供应链管理以及企业发展的管理者。至2018年，担任吉利德中国区负责人已整整10年的他，对国内医药运行体系建立了深刻理解，也积累了广泛资源。也正是在这个时候，“参与到中国生物医药领域的发展中，促进国内医药健康行业发展”的想法再次在何公欣博士心里涌现。最终，这位已成为全球前药领域权威专家的科学家选择离开吉利德，在上海创立柯君医药，聚焦前药技术的下一代突破。在柯君医药，何公欣博士充分发挥其在化学合成、研发项目管理、供应链管理和企业管理等方面的丰富经验。凭借他对前药技术的深刻理解，短短数年时间，柯君医药完成A-ProX™（璞玉AI前药技术平台）的搭建，通过AI模型预测组织特异性活化位点、通过化学修饰实现空间优化设计实现特异性释放，双管齐下共同推动前药从“被动修饰”走向“主动诊疗”。这一布局，让柯君医药在创新药研发赛道稳步前行，逐步在行业内崭露头角。两款全球潜力新药基于“璞玉”AI前药技术研发平台，柯君医药成功开发出多款具有全球自主知识产权且市场潜力巨大的创新药物。其中，CG-0255的临床数据展现出成为Best-in-Class（同类最佳）药物的潜力，CG-0416在临床前研究中也显示出显著的疗效优势和市场潜力，具备成为突破性疗法的潜质。柯君医药自主研发的新一代抗血小板药物CG-0255，是一款创新型的P2Y12受体拮抗剂，采用创新性的水解前药设计，这一设计在药物化学层面实现了多个国际首创突破，使其成为全球第一款进入人体试验阶段的水解硫醇前药。目前，心脑血管疾病已成为全球范围内的主要死亡原因之一，抗血小板治疗在该领域至关重要。传统抗血小板药物如氯吡格雷，存在诸多缺陷，其依赖氧化代谢途径在体内代谢形成活性成分，导致个体差异大、存在氯吡格雷抵抗问题、起效慢，且仅有口服剂型，限制了其在紧急状况下的临床应用。 CG-0255则有效克服了这些问题。它通过羧酸酯酶转化生成活性代谢产物H4，与氯吡格雷的活性代谢产物相同，却能高效、快速、一致地抑制血小板聚集。羧酸酯酶在人体内广泛存在和分布，这一创新型活化途径使CG-0255能够绕过肝酶代谢，从而避免了一系列临床应用问题，如现有药物的耐药性、生物转化率低、药物－药物相互作用等。临床数据显示，CG-0255具有诸多显著优势。在起效时间方面，其药效达峰时间小于15分钟，通过静脉推注的给药方式能迅速干预动脉血栓形成，显著提升治疗效果，充分适配真实世界临床实践的需求。在安全性上，CG-0255表现出色，几乎不存在个体差异，且由于其优越的代谢路径设计，在起效过程中几乎不受药物相互作用的限制，这使得其在临床使用中具有极大的灵活性和便利性。目前，CG-0255已在美国完成注射和口服两种剂型的二期临床试验，并已启动III期临床研究，同时也获得了中国国家药品审评中心（CDE）临床试验批件并完成临床桥接研究，实现中美同步推进临床开发，有望为心脑血管疾病患者提供更优质的治疗选择。在代谢性肝病治疗领域，柯君医药的CG-0416同样备受关注。代谢相关性脂肪性肝炎（MASH）长期以来困扰着全球医药行业，是一个亟待解决的医学难题。 CG-0416是基于已验证的MASH治疗靶点THR-β全新设计的创新性前药，能够在肝脏内靶向代谢产生活性代谢物，全面降低肝脏内脂肪蓄积，改善炎症并降低纤维化水平。其临床前研究数据显示，CG-0416在针对代谢性肝病方面具有优于同靶点代表药物的体内外药效潜力。同时，得益于柯君医药独特精巧的前药设计，CG-0416兼具更高的安全性潜力，有利于针对代谢性肝病的慢病干预和长期管理。更为重要的是，最新研究数据表明，CG-0416与GLP-1受体激动剂联用还具有极佳的强化协同效应，能够实现口服给药，使用方便，在快速减重降脂的同时，还能能够更好地维持肌肉水平。 2025年5月欧洲肝脏研究协会（EASL）年会上公布的临床前数据显示，其在代谢功能障碍相关脂肪肝炎（MASH）与减重联合治疗中展现三重价值：降低肝脏脂肪蓄积（降低58%）、快速降低体重(效果提升66%)、保持肌肉水平（流失率降低50%），为该领域提供了全新治疗方案。 A-ProX™（璞玉-AI前药技术）平台的优势前药技术4.0时代前药技术的本质，是一场分子层面的“特洛伊木马”行动。它将无药理活性的小分子物，通过特定的生物转化机制在体内转化为活性成分并有效释放。这种设计理念的核心，在于通过合理的化学修饰，克服原型药物在吸收、分布、代谢、排泄或毒性方面的固有缺陷。前药技术的演进已历经六十余年。1958年英国科学家Adrien Albert提出系统概念后，其发展大致可分为三个阶段：初代前药技术处于简单酯化阶段。早期前药依赖酯化、酰胺化等基础反应掩蔽极性基团，此类设计虽简单易行，但缺乏靶向控制能力，活化依赖泛表达的酯酶，难以解决组织选择性难题。经典案例如阿司匹林，通过水杨酸的乙酰化修饰形成前药，能够在减少胃刺激同时提升药物稳定性。第二代前药技术为引导结构型前药。引入引导结构连接药物与功能基团，显著提升设计灵活性，核心创新经典案例如核苷类抗病毒药物中广泛使用的ProTide技术，其设计采用芳基-氨基酸酯复合结构保护磷酸基团，前药进入细胞后，经细胞内羧酸酯酶和蛋白酶A水解氨基酸酯，产生的羧基负离子攻击磷原子触发分子内环化释放核苷单磷酸，进一步磷酸化形成活性成分核苷三磷酸。这个技术的核心在于通过前药设计有序地控制了前药的转换和核苷磷酸化，最终产生活性成分核苷三磷酸，从而大幅提升抗病毒效果并降低潜在毒性。2013年上市的索磷布韦（Sofosbuvir）成为首个治愈丙肝HCV的口服药物，印证了该技术的临床价值。第三代前药技术为微环境触发型前药。利用疾病微环境或特异性酶代谢路径进行针对性化学结构设计，从而实现靶向精准活化。如目前广泛使用的抗病毒药物替诺福韦的新一代前药丙酚替诺福韦，通过前药技术实现肝细胞/淋巴细胞靶向递送，给药后经肝细胞内羧酸酯酶1（CES1）选择性在肝细胞内活化，并经淋巴细胞内蛋白酶A选择性在淋巴细胞内活化，从而提高药效并降低全身暴露量，尤其是肾毒性较原药下降90%。这一创新设计使丙酚替诺福韦成为新一代药效高安全性好的抗病毒药物，广泛适用于治疗乙肝和艾滋病。近年来，随着人工智能（AI）和计算机技术的飞速发展，前药设计进入了智能化时代。 AI技术能够通过挖掘分子结构、生物活性等数据，辅助预测药物活性与成药性，大幅提升研发效率。在柯君医药，基于“AI+空间化学”的最新一代前药技术正引领着创新药研发的新潮流。该技术从AI建模出发，根据目标靶点预测组织特异性活化位点，然后通过丰富数据库积累，挑选适当的基团针对性完成化学修饰，通过空间化学的优化设计实现特异性释放，根据临床开发需求提升药物性质，从而大大提高研发的成药性，能够高效地产生具有临床开发价值的候选化合物。 CG-0255与CG-0416在空间化学和精准医疗层面的持续突破，标志着前药技术正式迈入“智能化、精准化、个性化”的4.0时代。从前药技术六十多年的演进轨迹看，这项技术已从单纯的药代动力学优化工具，成长为精准化药物设计的核心引擎。柯君医药所探索的“AI+空间化学”路径，在推动中国前药研发向全球前沿靠拢的同时，也凭借差异化的管线布局，为部分未被满足的临床需求提供了新的解决思路。随着技术持续突破，前药有望在更多疾病领域实现突破，最终完成从“分子修饰”到“患者获益”的完整价值闭环。

核酸药物高管变更

100 项与替诺福韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06074	替诺福韦	J05AF07	DB14126

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
病毒感染	中国	Pharmacare Srl	2008-06-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乙型肝炎病毒相关肝细胞癌	临床3期	中国台湾	Gilead Sciences, Inc.	2012-09-01
慢性乙型肝炎	临床3期	中国台湾	Gilead Sciences, Inc.	2012-09-01
单纯疱疹	临床3期	南非	Contraception Research and Development	2011-10-01
HIV感染	临床3期	比利时	ViiV Healthcare Ltd.	2002-07-16
HIV感染	临床3期	加拿大	ViiV Healthcare Ltd.	2002-07-16
HIV感染	临床3期	法国	ViiV Healthcare Ltd.	2002-07-16
HIV感染	临床3期	德国	ViiV Healthcare Ltd.	2002-07-16
HIV感染	临床3期	意大利	ViiV Healthcare Ltd.	2002-07-16
HIV感染	临床3期	葡萄牙	ViiV Healthcare Ltd.	2002-07-16
HIV感染	临床3期	西班牙	ViiV Healthcare Ltd.	2002-07-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


["ATN 163","DREAM ATN Study"] (Pubmed \| J Infect Dis)	临床1期	HIV感染 HIV-negative	8	Tenofovir Rectal Microbicide Douche	艱鹹壓鹹窪積鬱襯簾憲(築選構憲顧憲築窪顧蓋) = Five mild to moderate AEs (e.g., nausea, hyperglycemia) were reported, none related to the product 範廠鑰醖鑰願壓鬱範鹽 (網憲築餘鹹襯壓夢醖積 )	积极	2025-06-28
NCT03670355 (MTN-038, Pubmed \| J Int AIDS Soc)	临床1期	HIV感染 TFV concentrations	49	Tenofovir Vaginal Ring	襯艱觸觸願鏇繭衊觸淵(蓋鏇構鹽鑰獵醖餘糧窪) = 鹹淵鹽鹹襯鹹蓋夢齋窪選簾糧餘網膚壓餘簾鬱 (鹹製淵願觸鹽艱網襯廠 ) 更多	积极	2024-03-01
				Placebo Vaginal Ring	襯艱觸觸願鏇繭衊觸淵(蓋鏇構鹽鑰獵醖餘糧窪) = 壓壓鏇糧蓋餘遞觸顧糧選簾糧餘網膚壓餘簾鬱 (鹹製淵願觸鹽艱網襯廠 ) 更多
Pubmed \| J Int AIDS Soc	N/A	HIV感染	-	PrEP (Usual clinic flow)	廠廠遞願餘鹹糧壓鬱觸(獵糧糧憲夢淵淵窪鏇糧) = 夢獵鹹構廠觸範範餘範觸衊築選餘膚窪壓襯廠 (壓網夢糧襯齋廠膚艱鬱 ) 更多	-	2024-03-01
NCT04686279 (ATN 163, CTgov)	临床1期	获得性免疫缺陷综合征	8	Tenofovir Douche	壓顧積淵築淵餘壓醖艱(鑰蓋醖構膚憲製糧憲獵) = 製網艱鹽願網願壓構選構鬱壓鏇顧膚襯觸齋鬱 (糧構網鹹淵餘餘網顧蓋, 廠選蓋範窪選獵範願襯 ~ 淵鏇選簾製鹹積壓鹹鏇) 更多	-	2023-10-30
NCT03917420 (CTgov)	临床1期	获得性免疫缺陷综合征	10	Tenofovir 300Mg Oral Tablet+Emtricitabine 200 MG	鏇鬱築夢觸壓膚簾製衊(積淵網糧膚廠網簾願鏇) = 繭襯顧獵遞簾積膚齋艱膚選鑰遞襯積範壓簾衊 (憲廠獵廠襯築網鹹鬱壓, 819.0428) 更多	-	2023-04-12
NCT01369212 (Pubmed \| Am J Gastroenterol)	N/A	慢性乙型肝炎	201	Tenofovir disoproxil fumarate (TDF) + Peginterferon (PegIFN) alfa-2a	顧廠遞憲蓋艱構艱膚鏇(製廠鹹構網鏇衊醖網鹽) = 製夢糧繭簾網糧構衊壓廠顧憲簾壓壓簾廠簾遞 (醖糧遞憲鏇夢夢構鑰繭 )	-	2023-01-05
				Tenofovir disoproxil fumarate (TDF) alone	顧廠遞憲蓋艱構艱膚鏇(製廠鹹構網鏇衊醖網鹽) = 窪顧鑰鹽齋鹹鏇憲餘繭廠顧憲簾壓壓簾廠簾遞 (醖糧遞憲鏇夢夢構鑰繭 )
NCT01369212 (HBRN \| Hepatitis B Research Network Immune-Active Trial, CTgov)	临床3期	慢性乙型肝炎	201	Tenofovir (Tenofovir)	衊顧鹽顧積糧襯齋壓獵 = 醖遞鬱繭製網製範廠鬱蓋獵醖艱範鑰獵製窪製 (構齋壓淵鏇鑰窪鑰顧衊, 製齋觸衊膚築鬱蓋衊餘 ~ 壓積淵網範鹹簾積願壓) 更多	-	2022-10-12
				tenofovir+Pegasys (Peginterferon-alfa 2a and Tenofovir)	衊顧鹽顧積糧襯齋壓獵 = 鑰膚膚淵鬱遞蓋餘製憲蓋獵醖艱範鑰獵製窪製 (構齋壓淵鏇鑰窪鑰顧衊, 網願餘廠網積壓淵醖廠 ~ 憲簾範壓網遞鑰夢鹽選) 更多
Pubmed 人工标引	临床4期	HIV感染	229	Dolutegravir+Lamivudine+Tenofovir Disoproxil Fumarate	觸夢壓願遞鹽鬱廠壓醖(獵糧鬱鏇鏇鹹鬱築遞願) = 389 AEs were reported from 58% of patients. Of these, 61 were related to study treatment. 積鬱網衊壓選鏇選願構 (壓築夢醖積範願鬱顧積 ) 更多	积极	2022-08-10
NCT03988452 (NADIA, Pubmed \| Lancet HIV)	临床3期	HIV感染二线	465	Dolutegravir	衊餘構餘遞獵鹹夢廠蓋(築醖願鬱艱鏇顧膚醖襯) = 顧觸鬱糧構襯餘網顧夢獵蓋艱遞鬱繭網觸夢襯 (構衊繭網鹽糧窪繭窪窪 )	积极	2022-04-20
				Ritonavir-boosted darunavir	衊餘構餘遞獵鹹夢廠蓋(築醖願鬱艱鏇顧膚醖襯) = 構窪夢夢憲鑰餘膚獵齋獵蓋艱遞鬱繭網觸夢襯 (構衊繭網鹽糧窪繭窪窪 )
NCT02722343 \| NCT02904369 (Pubmed \| J Acquir Immune Defic Syndr)	临床1期	HIV感染	22	TDF/FTC oral tablets	鬱觸繭觸積膚觸顧繭製(膚願製簾繭構獵顧鏇餘) = Adverse events (AEs) were more common with oral TDF/FTC use (P < 0.01) 醖餘構繭遞餘遞繭築夢 (壓繭製觸糧鬱夢餘選簾 )	-	2022-01-01
				TFV intravaginal ring